CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 414 filers reported holding CRISPR THERAPEUTICS AG in Q4 2020. The put-call ratio across all filers is 1.10 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $306,428 | -17.9% | 6,751 | +1.5% | 0.00% | -50.0% |
| Q2 2023 | $373,387 | +11.1% | 6,651 | -10.5% | 0.00% | +100.0% |
| Q1 2023 | $336,149 | +3.1% | 7,432 | +49.1% | 0.00% | 0.0% |
| Q3 2022 | $326,000 | -6.3% | 4,983 | -13.0% | 0.00% | 0.0% |
| Q2 2022 | $348,000 | -25.8% | 5,729 | -23.4% | 0.00% | 0.0% |
| Q1 2022 | $469,000 | -20.5% | 7,479 | -4.0% | 0.00% | 0.0% |
| Q4 2021 | $590,000 | -74.3% | 7,787 | -62.0% | 0.00% | -83.3% |
| Q3 2021 | $2,295,000 | -88.3% | 20,501 | -83.1% | 0.01% | -88.2% |
| Q2 2021 | $19,684,000 | +2990.1% | 121,591 | +2224.4% | 0.05% | +2450.0% |
| Q1 2021 | $637,000 | -93.3% | 5,231 | -91.6% | 0.00% | -93.5% |
| Q4 2020 | $9,526,000 | +991.2% | 62,216 | +496.1% | 0.03% | +933.3% |
| Q3 2020 | $873,000 | +254.9% | 10,438 | +211.8% | 0.00% | +200.0% |
| Q2 2020 | $246,000 | -16.3% | 3,348 | -30.6% | 0.00% | 0.0% |
| Q4 2019 | $294,000 | – | 4,823 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $27,989,046 | 33.20% |
| Gilfoyle Management LLC | 100 | $4,842 | 15.90% |
| NEA Management Company, LLC | 1,587,854 | $89,142,124 | 6.80% |
| ARK Investment Management | 7,338,447 | $411,980,394 | 2.73% |
| Nikko Asset Management Americas, Inc. | 3,533,357 | $198,327,328 | 2.09% |
| Del-Sette Capital Management, LLC | 33,661 | $1,889,729 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Merlin Capital, Inc | 8,802 | $494,144 | 1.67% |
| Green Alpha Advisors, LLC | 34,373 | $1,929,700 | 1.27% |